Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
A Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of an Engineered Mitochondrial Vaccine in Treatment of Advanced Solid Tumors
West China Hospital
12 participants
May 9, 2025
INTERVENTIONAL
Conditions
Summary
This study is a dose-escalation, prospective clinical trial to assess the safety, tolerability, and preliminary therapeutic efficacy of engineered mitochondria expressing specific tumor antigen in patients with advanced solid tumors.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants were assigned to one of four dose-escalation groups (25 μg, 50 μg, 100 μg, or 200 μg per dose) and received subcutaneous injections of the engineered mitochondrial vaccine in a prime-boost schedule. The regimen consisted of 3 doses of primary immunization, 1 dose of boost immunization and subsequent personalized treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06927297